

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-17 (cancelled)

18. (currently amended): An antibody which specifically reacts with a human IL-11 Receptor (IL-11R) protein comprising, wherein said IL-11R protein comprises an amino acid sequence from SEQ ID NO:2 selected from the group consisting of amino acids 26 to 111, amino acids 112 to 365, amino acids 366 to 390, and amino acids 391 to 422.

Claims 19-38 (cancelled)

39. (previously amended): The antibody of claim 18, wherein said antibody is a neutralizing antibody.

40. (previously amended): The antibody of claim 18, wherein said antibody blocks binding of IL-11 to a human IL-11 receptor.

41. (previously amended): The antibody of claim 18, wherein said antibody is a polyclonal antibody.

42. (previously amended): The antibody of claim 18, wherein said antibody is a monoclonal antibody.

43. (previously amended): The antibody of claim 18, wherein said antibody specifically reacts with a protein comprising the amino acid sequence of SEQ ID NO:2.

44. (previously amended): The antibody of claim 18, wherein said antibody specifically reacts with a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 26 to 422.

45. (previously amended): The antibody of claim 18, wherein said antibody specifically reacts with a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 26 to 365.

46. (previously amended): The antibody of claim 18, wherein said antibody specifically reacts with a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 391 to 422.

47. (previously amended): The antibody of claim 18, wherein said antibody specifically reacts with a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 112 to 422.

48. (previously amended): The antibody of claim 18, wherein said antibody specifically reacts with a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 112 to 365.

49. (previously amended): The antibody of claim 18, wherein said antibody specifically reacts with a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 26 to 359.

50. (previously amended): The antibody of claim 18, wherein said antibody specifically reacts with a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 26 to 345.

51. (previously amended): The antibody of claim 18, wherein said antibody specifically reacts with a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 26 to 324.

52. (previously amended): The antibody of claim 62, wherein said antibody is obtained using as an immunogen a protein with a cysteine residue at the carboxyl terminus, wherein said protein comprises an amino acid sequence from SEQ ID NO:2 selected from the group consisting of amino acids 26 to 111, amino acids 112 to 365, amino acids 366 to 390, and amino acids 391 to 422.

53. (previously amended): The antibody of claim 62, wherein said antibody is obtained using as an immunogen a protein with tyrosine residues replaced with sulfated tyrosine residues.

54. (cancelled)

55. (previously amended): The antibody of claim 62, wherein said immunogen is conjugated to a hapten.

56. (previously amended): The antibody of claim 55, wherein said hapten is keyhole limpet hemocyanin (KLH).

57. (previously amended): A pharmaceutical composition comprising the antibody of claim 18 and a pharmaceutically acceptable carrier.

58. (currently amended): A neutralizing antibody that binds specifically to a human IL-11 Receptor (IL-11R) protein comprising, wherein said IL-11R protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2 from amino acids 26 to 111, SEQ ID NO:2 from amino acids 112 to 365, SEQ ID NO:2 from 366 to 390, and SEQ ID NO:2 from 391 to 422, wherein said neutralizing antibody blocks binding of IL-11 to a human IL-11 receptor.

59. (previously added): A pharmaceutical composition comprising the composition of claim 58 and a pharmaceutically acceptable carrier.

60. (previously added): The antibody of claim 18, wherein said antibody specifically reacts with a protein comprising an amino acid sequence of SEQ ID NO:2 from 26 to 111.

61 (previously added): The antibody of claim 18, wherein said antibody specifically reacts with a protein comprising an amino acid sequence of SEQ ID NO:2 from 366 to 390.

62 (currently amended): An antibody obtained using as an immunogen a an IL-11 Receptor ("IL-11R") protein comprising, wherein said IL-R protein comprises an amino acid sequence from SEQ ID NO:2 selected from the group consisting of amino acids 26 to 111, amino acids 112 to 365, amino acids 366 to 390, and amino acids 391 to 422.

63 (previously added): The antibody of claim 18, wherein said antibody is an isolated antibody.

64 (previously added): The antibody of claim 58, wherein said antibody is an isolated antibody.

65 (previously added): The antibody of claim 62, wherein said antibody is an isolated antibody.